title: Utilization trends and positive biopsy rates for prostate biopsies in the United States: 2005 to 2011.
abstract: This article assesses the positive biopsy rate and core sampling pattern in patients undergoing needle biopsy of the prostate in the United States at a national reference laboratory (NRL) and anatomic pathology laboratories integrated into urology group practices, and analyzes the relationship between positive biopsy rates and the number of specimen vials per biopsy. For the years 2005 to 2011 we collected pathology data from an NRL, including number of urologists and urology practices referring samples, total specimen vials submitted for prostate biopsies, and final pathologic diagnosis for each case. The diagnoses were categorized as benign, malignant, prostatic intraepithelial neoplasia, or atypical small acinar proliferation. Over the same period, similar data were gathered from urology practices with in-house laboratories performing global pathology services (urology practice laboratories; UPLs) as identified by a survey of members of the Large Urology Group Practice Association. For each year studied, positive biopsy rate and number of specimen vials per biopsy were calculated in aggregate and separately for each site of service. From 2005 to 2011, 437,937 biopsies were submitted in > 4.23 million vials (9.4 specimen vials/biopsy); overall positive biopsy rate was 40.3%-this was identical at both the NRL and UPL (P = .97). Nationally, the number of specimen vials per biopsy increased sharply from a mean of 8.8 during 2005 to 2008 to a mean of 10.3 from 2009 to 2011 (difference, 1.5 specimen vials/biopsy; P = .03). For the most recent 3-year period (2009-2011), the difference of 0.6 specimen vials per biopsy between the NRL (10.0) and UPL (10.6) was not significant (P = 0.08). Positive biopsy rate correlated strongly (P < .01) with number of specimen vials per biopsy. The positive prostate biopsy rate is 40.3% and is identical across sites of service. Although there was a national trend toward increased specimen vials per biopsy from 2005 to 2011, from 2009 to 2011 there was no significant difference in specimen vials per biopsy across sites of service. Increased cancer detection rate correlated significantly with increased number of specimens examined. Segregation of prostate biopsy cores into 10 to 12 unique specimen vials has been widely adopted by urologists across sites of service.
authors.affiliation: Integrated Medical Professionals, PLLC, Melville, NY.
authors.forename: Deepak A
authors.initials: DA
authors.lastname: Kapoor
authors.affiliation: Bostwick Laboratories, Inc., Uniondale, NY.
authors.forename: David G
authors.initials: DG
authors.lastname: Bostwick
authors.affiliation: Integrated Medical Professionals, PLLC, Melville, NY.
authors.forename: Savvas E
authors.initials: SE
authors.lastname: Mendrinos
authors.affiliation: Integrated Medical Professionals, PLLC, Melville, NY.
authors.forename: Ann E
authors.initials: AE
authors.lastname: Anderson
authors.affiliation: Integrated Medical Professionals, PLLC, Melville, NY.
authors.forename: Carl A
authors.initials: CA
authors.lastname: Olsson
keywords: National reference laboratory; Prostate biopsy; Prostate cancer; Urology practice laboratories; Utilization trends